Drug-induced interstitial lung disease after chemoimmunotherapy for extensive-stage small cell lung cancer

被引：4

作者：

Fukuda, Kiyoko ^{[1
]}

Katsurada, Naoko ^{[1
]}

Kawa, Yoshitaka ^{[2
]}

Satouchi, Miyako ^{[2
]}

Kaneshiro, Kazumi ^{[3
]}

Matsumoto, Masataka ^{[3
]}

Takamiya, Rei ^{[4
]}

Hatakeyama, Yukihisa ^{[4
]}

Dokuni, Ryota ^{[5
]}

Matsumura, Kanoko ^{[6
]}

Katsurada, Masahiro ^{[7
]}

Nakata, Kyosuke ^{[8
]}

Yoshimura, Sho ^{[9
]}

Tachihara, Motoko ^{[1
]}

机构：

[1] Kobe Univ, Dept Internal Med, Div Resp Med, Grad Sch Med, 7-5-1 Kusunoki Cho,Chuo Ku, Kobe 6500017, Japan

[2] Hyogo Canc Ctr, Dept Thorac Oncol, Akashi, Japan

[3] Kita Harima Med Ctr, Dept Resp Med, Ono, Japan

[4] Akashi Med Ctr, Dept Resp Med, Akashi, Japan

[5] Hyogo Prefectural Awaji Med Ctr, Dept Resp Med, Sumoto, Japan

[6] Takatsuki Gen Hosp, Dept Resp Med, Takatsuki, Japan

[7] Hyogo Prefectural Tamba Med Ctr, Dept Internal Med, Tamba, Japan

[8] Konan Med Ctr, Dept Resp Med, Kobe, Japan

[9] Steel Mem Hirohata Hosp, Dept Resp Med, Himeji, Japan

来源：

HELIYON | 2023年 / 9卷 / 10期

关键词：

Small cell lung cancer; Interstitial lung abnormalities; Drug-induced interstitial lung disease; Immunotherapy; PNEUMONITIS; NIVOLUMAB; DOCETAXEL;

D O I：

10.1016/j.heliyon.2023.e20463

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Objectives: The combination of chemotherapy and immune checkpoint inhibitors (chemo-ICI) has become the new standard of treatment for extensive-stage small cell lung cancer (ES-SCLC). Recently, slight changes in interstitial shadows, defined as interstitial lung abnormalities (ILA), have been identified. In patients with ES-SCLC who received chemo-ICI, there are limited data on the incidence of drug-induced interstitial lung disease (D-ILD) in daily practice and the association between the development of D-ILD and ILA in the baseline computed tomography (CT). Materials and methods: A multicenter, retrospective study was conducted to investigate the incidence of D-ILD, the risk factors for developing D-ILD, progression-free survival (PFS), and overall survival (OS) in patients with ES-SCLC who received chemo-ICI between August 2019 and November 2021.Results: This study enrolled 70 patients (median age, 71 years; including 58 men) from nine institutions in Japan. There were 62 patients (89%) treated with carboplatin/etoposide/atezolizumab and 8 patients treated with carboplatin or cisplatin/etoposide/durvalumab. Twenty-nine patients (41.4%) were found to have ILA at baseline CT. Eleven patients (15.7%) developed DILD. The proportion of patients with ILA was significantly higher in the group who developed DILD than in the group who did not (9/11 (81.8%) vs. 20/59 (33.9%), respectively, P = 0.0057). In addition, the frequency of ground glass attenuation (GGA) and reticulation was higher in patients who developed D-ILD. There was no significant difference in PFS and OS between patients who developed D-ILD and those who did not (median PFS, 8.0 (95% confidence interval (CI), 5.5-9.5) months vs. 5.0 (95% CI, 4.5-5.6) months, respectively, P = 0.11 and median OS, not reached (NR) (95% CI, 8.7-NR) vs. 18.2 (95% CI, 13.2-NR) months, respectively, P = 0.20).Conclusion: The incidence of D-ILD in patients with ES-SCLC who received chemo-ICI in clinical practice was higher than that in clinical trials. Patients with pre-existing ILA were more likely to develop D-ILD.

引用

页数：8

共 24 条

[1] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Borghaei, H. ;

Paz-Ares, L. ;

Horn, L. ;

Spigel, D. R. ;

Steins, M. ;

Ready, N. E. ;

Chow, L. Q. ;

Vokes, E. E. ;

Felip, E. ;

Holgado, E. ;

Barlesi, F. ;

Kohlhaeufl, M. ;

Arrieta, O. ;

Burgio, M. A. ;

Fayette, J. ;

Lena, H. ;

Poddubskaya, E. ;

Gerber, D. E. ;

Gettinger, S. N. ;

Rudin, C. M. ;

Rizvi, N. ;

Crino, L. ;

Blumenschein, G. R. ;

Antonia, S. J. ;

Dorange, C. ;

Harbison, C. T. ;

Finckenstein, F. Graf ;

Brahmer, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639

[2] Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer [J].

Brahmer, Julie ;

Reckamp, Karen L. ;

Baas, Paul ;

Crino, Lucio ;

Eberhardt, Wilfried E. E. ;

Poddubskaya, Elena ;

Antonia, Scott ;

Pluzanski, Adam ;

Vokes, Everett E. ;

Holgado, Esther ;

Waterhouse, David ;

Ready, Neal ;

Gainor, Justin ;

Aren Frontera, Osvaldo ;

Havel, Libor ;

Steins, Martin ;

Garassino, Marina C. ;

Aerts, Joachim G. ;

Domine, Manuel ;

Paz-Ares, Luis ;

Reck, Martin ;

Baudelet, Christine ;

Harbison, Christopher T. ;

Lestini, Brian ;

Spigel, David R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) :123-135

[3]

Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI [10.3322/caac.21492, 10.3322/caac.21609]

[4] Original Research Pembrolizumab plus chemotherapy-induced pneumonitis in chemo-nai•ve patients with non-squamous non-small cell lung cancer: A multicentre, retrospective cohort study [J].

Fujimoto, Daichi ;

Miura, Satoru ;

Yoshimura, Kenichi ;

Wakuda, Kazushige ;

Oya, Yuko ;

Yokoyama, Toshihide ;

Yokoi, Takashi ;

Asao, Tetsuhiko ;

Tamiya, Motohiro ;

Nakamura, Atsushi ;

Yoshioka, Hiroshige ;

Haratani, Koji ;

Teraoka, Shunsuke ;

Tokito, Takaaki ;

Murakami, Shuji ;

Tamiya, Akihiro ;

Itoh, Shoichi ;

Yokouchi, Hiroshi ;

Watanabe, Satoshi ;

Yamaguchi, Ou ;

Tomii, Keisuke ;

Yamamoto, Nobuyuki .

EUROPEAN JOURNAL OF CANCER, 2021, 150 :63-72

[5] Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer [J].

Gadgeel, Shirish ;

Rodriguez-Abreu, Delvys ;

Speranza, Giovanna ;

Esteban, Emilio ;

Felip, Enriqueta ;

Domine, Manuel ;

Hui, Rina ;

Hochmair, Maximilian J. ;

Clingan, Philip ;

Powell, Steven F. ;

Cheng, Susanna Yee-Shan ;

Bischoff, Helge G. ;

Peled, Nir ;

Grossi, Francesco ;

Jennens, Ross R. ;

Reck, Martin ;

Garon, Edward B. ;

Novello, Silvia ;

Rubio-Viqueira, Belen ;

Boyer, Michael ;

Kurata, Takayasu ;

Gray, Jhanelle E. ;

Yang, Jing ;

Bas, Tuba ;

Pietanza, M. Catherine ;

Garassino, Marina C. .

JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (14) :1505-+

[6] First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer [J].

Horn, L. ;

Mansfield, A. S. ;

Szczesna, A. ;

Havel, L. ;

Krzakowski, M. ;

Hochmair, M. J. ;

Huemer, F. ;

Losonczy, G. ;

Johnson, M. L. ;

Nishio, M. ;

Reck, M. ;

Mok, T. ;

Lam, S. ;

Shames, D. S. ;

Liu, J. ;

Ding, B. ;

Lopez-Chavez, A. ;

Kabbinavar, F. ;

Lin, W. ;

Sandler, A. ;

Liu, S. V. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (23) :2220-2229

[7] Investigation of the freely available easy-to-use software 'EZR' for medical statistics [J].

Kanda, Y. .

BONE MARROW TRANSPLANTATION, 2013, 48 (03) :452-458

[8] Nivolumab-induced interstitial lung disease analysis of two phase II studies patients with recurrent or advanced non-small-cell lung cancer [J].

Kato, Terufumi ;

Masuda, Noriyuki ;

Nakanishi, Yoichi ;

Takahashi, Masashi ;

Hida, Toyoaki ;

Sakai, Hiroshi ;

Atagi, Shinji ;

Fujita, Shiro ;

Tanaka, Hiroshi ;

Takeda, Koji ;

Satouchi, Miyako ;

Namba, Yoshinobu ;

Tamura, Tomohide .

LUNG CANCER, 2017, 104 :111-118

[9] Chemoradiotherapy for limited-stage small-cell lung cancer and interstitial lung abnormalities [J].

Kobayashi, Haruki ;

Wakuda, Kazushige ;

Naito, Tateaki ;

Mamesaya, Nobuaki ;

Omori, Shota ;

Ono, Akira ;

Kenmotsu, Hirotsugu ;

Murakami, Haruyasu ;

Endo, Masahiro ;

Harada, Hideyuki ;

Gon, Yasuhiro ;

Takahashi, Toshiaki .

RADIATION ONCOLOGY, 2021, 16 (01)

[10] Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer [J].

Nakanishi, Yu ;

Masuda, Takeshi ;

Yamaguchi, Kakuhiro ;

Sakamoto, Shinjiro ;

Horimasu, Yasushi ;

Nakashima, Taku ;

Miyamoto, Shintaro ;

Tsutani, Yasuhiro ;

Iwamoto, Hiroshi ;

Okada, Morihito ;

Hattori, Noboru ;

Fujitaka, Kazunori ;

Miyata, Yoshihiro ;

Hamada, Hironobu .

RESPIRATORY INVESTIGATION, 2019, 57 (05) :451-459

← 1 2 3 →